THE POSPONT RESULTS OF SWITCHING ON TOPIRAMAT GENERICS AT PATIENTS WITH EPILEPSY
Abstract: long-term results are presented for a switch from the brand formulation to generic topiramate preparations in adult patients suffering from symptomatic or cryptogenic focal epilepsy. A total of 110 study subjects (49 men and 61 women aged from 21 to 70 years) and 22 reference controls were...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2016-05-01
|
| Series: | Эпилепсия и пароксизмальные состояния |
| Subjects: | |
| Online Access: | https://www.epilepsia.su/jour/article/view/104 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract: long-term results are presented for a switch from the brand formulation to generic topiramate preparations in adult patients suffering from symptomatic or cryptogenic focal epilepsy. A total of 110 study subjects (49 men and 61 women aged from 21 to 70 years) and 22 reference controls were followed up for a period of 18 – 29 months after the switch. Over half the patients had a clinical condition that was worse than at baseline. Drug-resistant epilepsy had formed in 37 % patients with a remission at baseline. Patients who had developed a remission following start-up Topamax therapy after 2 to 4 treatment attempts, at 18 – 29 months after the switch, had similar drug-resistance (р=0.803) and remission rates in the two groups. The number of anti-epilepsy medicines and their doses had to be increased in 73 % and 92 % of cases, respectively. |
|---|---|
| ISSN: | 2077-8333 2311-4088 |